Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (53)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kruuse, C.
Right arrow Articles by Olesen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kruuse, C.
Right arrow Articles by Olesen, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 126, No. 1, 241-247, January 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg009

Migraine can be induced by sildenafil without changes in middle cerebral artery diameter

Christina Kruuse, Lars Lykke Thomsen, Steffen Birk and Jes Olesen

Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Copenhagen, Denmark

Correspondence to: C. Kruuse, MD, Department of Neurology, Glostrup Hospital, University of Copenhagen, DK-2600 Glostrup, Denmark E-mail: ckruuse{at}dadlnet.dk

Migraine is considered a neurovascular disease involving dilatation of cerebral arteries. Nitric oxide (NO) donors induce dilatation of cerebral and extracranial arteries and migraine, but NO has several mechanisms of action in addition to its cyclic guanosine monophosphate (cGMP)-mediated vasodilatation. We examined whether sildenafil (Viagra®), a selective inhibitor of cGMP-hydrolysing phosphodiesterase 5 (PDE5), which acts exclusively by increasing cGMP, can induce migraine and dilatation of cerebral arteries. We included 12 patients with migraine without aura in this double-blind, placebo-controlled crossover study, in which placebo or sildenafil 100 mg was administered orally on two separate days. Blood flow velocity in the middle cerebral artery (Vmca) was recorded by transcranial Doppler ultrasonography and regional cerebral blood flow in the territory of the middle cerebral artery (rCBFmca) was measured using SPECT (single photon emission computed tomography) and xenon 133 inhalation. Radial and temporal artery diameters were studied using high-frequency ultrasonography. Headache response, tenderness of pericranial muscles, blood pressure and heart rate were measured repeatedly. We found that migraine attack was induced by sildenafil in 10 of 12 migraine patients and by placebo in two of 12 patients (P = 0.01). Vmca (P = 0.1) and rCBFmca (P = 0.93) remained unchanged after sildenafil. Temporal (P = 0.47) and radial (P = 0.87) artery diameter and pericranial tenderness (P = 0.16) were unaffected by sildenafil. Systolic and diastolic blood pressures were unchanged but heart rate increased from a mean of 62 ± 2 to 74 ± 3 beats/min (P = 0.01) after sildenafil. Our results demonstrate that migraine may be induced via a cGMP-dependent mechanism, and we show for the first time that this occurs without initial dilatation of the middle cerebral artery. We propose that triggering mechanisms may reside within the perivascular sensory nerve terminals or the brainstem. However, other sites of action may also be possible and future studies are needed to elucidate this. In the clinical use of sildenafil, patients who have migraine should be informed about the risk of migraine attacks.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BrainHome page
G. G. Schoonman, J. van der Grond, C. Kortmann, R. J. van der Geest, G. M. Terwindt, and M. D. Ferrari
Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study
Brain, August 1, 2008; 131(8): 2192 - 2200.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
P. J. Goadsby
Advances in the understanding of headache
Br. Med. Bull., October 5, 2005; 73-74(1): 83 - 92.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. Diomedi, F. Sallustio, B. Rizzato, F. Ferrante, G. Leone, E. Spera, M. Scarfini, and G. Bernardi
Sildenafil increases cerebrovascular reactivity: A transcranial Doppler study
Neurology, September 27, 2005; 65(6): 919 - 921.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
H. A. Ghofrani, F. Reichenberger, M. G. Kohstall, E. H. Mrosek, T. Seeger, H. Olschewski, W. Seeger, and F. Grimminger
Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Ann Intern Med, August 3, 2004; 141(3): 169 - 177.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
D. Levy and A. M. Strassman
Modulation of Dural Nociceptor Mechanosensitivity by the Nitric Oxide-Cyclic GMP Signaling Cascade
J Neurophysiol, August 1, 2004; 92(2): 766 - 772.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.